Investor Relations
Company Information
- Summary of the period
- Calendar
- Financial Reports
- Shares
- Presentations
- Corporate Governance
- In the Press
“Net sales increased with 195% to 100 MSEK”
FOURTH QUARTER: October 1st – December 31st 2020
(Numbers in parentheses refer to outcomes during the corresponding period of the previous year.)
• Net revenue amounted to 100 640 KSEK (34 084 KSEK), a increase of 195%.
• Organic, currency-adjusted growth amounted to 32% .
• Operating profit begore depreciation (EBITDA) amounted to 31 577 KSEK (8 246 KSEK),
corresponding to a increase of 283% corresponding to an EBITDA-margin of 31,3% (24,1%).
• Operating profit after depreciation (EBIT) amounted to 25 338 KSEK (6 584 KSEK),
corresponding to a increase of 285% and an EBIT-margin of 25,1% (19,3%).
• Profit after tax amounted to 20 448 KSEK (5 722 KSEK).
• Earnings per share, based on 20 265 178 shares 1,01 SEK (0.36 SEK).
• As of December 31st 2020 cash amounted to 284 081 KSEK (45 737 KSEK).
Full year 2020: January 1st – December 31st 2020
(Numbers in parentheses refer to outcomes during the corresponding period of the previous year.)
• Net revenue amounted to 239 946 TSEK (126 769 KSEK), an increase of 89%.
• Organic, currency-adjusted growth amounted to 19% .
• Operating profit before depreciation (EBITDA) amounted to 70 301 TSEK (39 531 KSEK),
corresponding to an increase of 78% corresponding to an EBITDA-margin of 29,3% (31,2%).
• Operating profit after depreciation (EBIT) amounted to 60 366 KSEK (36 914 KSEK),
corresponding to an increase of 64% and an EBIT-margin of 25.1% (29,1%).
• Acquisition costs amounted to 5 254 KSEK . Adjusted for this, EBIT amounted to 65 620 KSEK, corresponding to an EBIT margin of 27,3%.
• Profit after tax amounted to 48 531 KSEK (29 913 KSEK).
• Earnings per share calculated on 17 358 303 shares 2,80 SEK (1.90 SEK).
• Cash flow from operating activities amounted to 30 596 TSEK (33 128 KSEK).
• Foreign exchange gains amounted to 5 091 KSEK.
• The Board of Directors proposes a dividend of 0,80 SEK per share.
• The Board of Directors will propose to the Annual General Meeting to decide on a split of the company’s shares by 4:1.
• Swedencare’s new financial goal is to achieve a turnover of 2 BSEK in 2025 with an EBIT margin exceeding 30%.
Significant events during the fourth quarter:
• Swedencare AB (publ) secures exclusive rights for the purchase of raw materials for dental products for the North American market.
• Swedencare AB (publ) secures the most important production market through exclusive rights for the purchase of raw materials for dental products for Europe.
• Swedencare AB (publ) determines the additional purchase price for the acquisition of Animal
Pharmaceuticals to the maximum amount of approximately 87 MSEK (10 MUSD).
• Swedencare AB (publ) signs an agreement to acquire Holden2, an American e-commerce company focusing on pet health products.
• Swedencare AB (publ) carries out a directed new emission of 750 000 shares and is thus provided with 222 MSEK, which, after issue costs of 3 MSEK, provided a net contribution of approximately
219 MSEK to partially finance the acquisition of Holden2.
• Swedencare AB’s (publ) powder product, ProDen PlaqueOff® CAT, has been approved by VOHC.
Significant events after the fourth quarter:
• Canagans Dental dry food, which contains Swedencare’s ProDen PlaqueOff®, has been approved by VOHC.
• Swedencare AB (publ) has completed the acquisition of Holden2 and part of the purchase is settled
with a non-cash issue.
Words from the CEO:
Both organic and acquired business deliver – first step towards our new financial targets.
The revenue for the fourth quarter 2020 was 100,6 MSEK which is an increase by 195% in comparison to Q4 2019 and the EBITDA-results increased by 283% to 31,5 MSEK, equaling a margin of 31,3%. The strong momentum of the industry was maintained throughout Q4 despite the continued effects of the pandemic worldwide.
The fact that we would deliver a record report in terms of revenue and result was to be expected due to our acquisitions of Animal Pharmaceuticals and Nutravet, both which are included in the numbers from October 1st, 2020, but the fact that we also reached an organic growth exceeding 32% is a true sign of strength given the global situation. The pandemic keeps affecting us by extended production- and delivery time from most of our partners. However, we are managing fairly well, only seeing a minor effect on sales, which otherwise would have been higher.
Basically, all markets globally report a growth in the number of registered dogs and cats. On the more mature markets it is not unusual with growth figures for 2020 exceeding 10%, to be compared to numbers between 1-2% annually during the last ten years. A fast growing pet population makes a great foundation for a continually strong Pet Health Care market.
As I mentioned in our latest quarterly report, we continue with many and some larger scale marketing projects. Brand building activities alongside more sales focused projects have been implemented and will keep being launched in 2021.
The integration of our new acquisitions proceeds very well, as expected. We have been transparent in regard to what we look for in our acquisitions – growth potential, profitability and not least that we look for entrepreneurs who wants to continue growing individually as well as an important part of the Swedencare family. It is a true pleasure to be part of and get reports from all the various projects and collaborations that take place within our group. Our strategy that the ordinary operations should keep on going as before while we gradually add synergies has turned out very well. We are only just at the beginning of this journey and I look forward to being able to share more information about new collaborations among our group companies in future reports.
To name some of these projects, we have streamlined our sales of ProDen PlaqueOff® via Amazon, generating a strong increase in sales as well as improved the pricing to end consumer. During Q1 2021 we are launching a ProDen PlaqueOff® Soft Chew developed by Stratford and SwedencareUSA will be launching a number of Stratford products to the Pet Specialty sector under the Swedencare brand name. The North American market, the largest in the world, will remain being our largest market going forward. All American subsidiaries had a strong quarter and the integration of Animal Pharm and Stratford are running according to plan. Before the end of Q1 2021 Stratford will have taken over the responsibility for finances, inventory, fulfillment which will impact the bottom line and growth favorably. SwedencareUSA has relocated to Houston, Texas, mainly for logistical advantages due to the fact that our Dental Bones are produced in Texas. Furthermore, we have started a new subsidiary, Tillverka Inc., which will start producing ProDen PlaqueOff® in the SwedencareUSA facility.
By starting inhouse production we will be able to increase our margins and secure the access of finished goods. Our goal is that at least 50 % of all the ProDen PlaqueOff® powder for the North American market will be produced in house already in 2021.
In the UK we see the same strong trend as in the US and both our subsidiaries have had a very strong growth. Needless to say, Brexit has been a cloud of uncertainty, but despite having moved our inventory to Ireland we have been able to manage the situation well and have not had any serious effects so far in Q1. Amazon keeps being an essential channel of sales of ProDen PlaqueOff® and for Nutravet the quarter has been affected positively by two new product launches. We will also shortly be introducing Nutravet on the Greek market through our subsidiary. The knowledge gained through this process will be used to build a “go to market strategy” which will be used on new markets in the future.
In Europe we also see high growth with record high quarters in both Spain and Greece as well as strong sales in France and the Nordic Region.
In the rest of the world Asia dominates with large orders to China and South Korea and the current year is predicted to continue strongly. We have just finished this year’s marketing plan for China thus, I have great expectations for China 2021. In South Korea we will launch more products and it will continue to be the external market with the widest range of Swedencare products.
Last year we not only managed to make a large number of business development projects and reach high growth numbers, but we also ended the year by signing yet another acquisition at the end of Q4 2020. With the acquisition of the American company Holden2 we secure both large online sales numbers as well as unique competence within online sales. Holden2 is another acquisition that will make a big difference for the group. Apart from online competence, they have several brands where PetMD® and Vetwell® are platforms where we effectively can launch other Swedencare products and at the same time launch PetMD® on the leading European online platforms during the year. Holden2 has had a fantastic growth in 2020 and the start of 2021 seems to continue equally well. Our strategy of acquisitions is based on a simple philosophy – we look for companies that are similar to ours i.e. profitable companies with high growth numbers, led by entrepreneurs sharing our goal to create a world leading group within Pet Health Care. I am very pleased that we managed to procure our large logistic center building in Ireland– we will need it – considering what we will be creating these next couple of years.
I now look forward to getting to travel again and be able to meet all my new colleagues, partners and customers.
Our new financial targets are inspiring, and I will do my utmost to reach these with good margin when it’s time to check off. It will not be an easy task, but I am convinced that together with my fantastic organization we will deliver.
Winter greetings,
Håkan Lagerberg, CEO
Malmö, February 18th 2021
Read the yearend report in its entirety here: (Print) (Screen)
FOR FURTHER INFORMATION:
Håkan Lagerberg, CEO
Tel: +46 (0)735-170 170, E-mail: hakan.lagerberg@swedencare.se
Jenny Graflind, CFO
Tel: +46 (0)739-448 554, E-mail: jenny.graflind@swedencare.se
Swedencare develop, produce partly in own factory, market and sell premium products on the global and fast-growing market within animal healthcare for cats, dogs and horses. The Company has a wide range of strong brands and products within most therapy areas, which includes own vet-exclusive brands as well as ProDen PlaqueOff® as the largest for oral health to dogs and cats. Swedencare’s headquarter is located in Malmö and the products are represented on approximately fifty markets in all parts of the world to veterinarians, pet shops and online through a distribution network including eleven subsidiaries as well as an international distribution network. Swedencare’s sales have increased significantly over the last few years with strong margins and profits.
This information is information that Swedencare AB (publ) is required to disclose in accordance with the EU Market Abuse Regulation and the Securities Market Act. The information was submitted for publication on February 18, 2021 08.30 CET.
Calendar Period: 2021
| Date | Event |
|---|---|
| 29 April, 2021 | Interim Report Q1 2021 |
| 29 April, 2021 | Annual General Meeting, Kl. 14:00, Medeon Science Park |
| 29 July, 2021 | Interim Report Q2 2021 |
| 28 October, 2021 | Interim Report Q3 2021 |
Links to quarterly reports, annual reports
and prospectus for Swedencare AB (publ).
- Financial Reports
-
Interim reports and Quarterly presentations
-
2020
-
Q1
-
Reports
Presentations
Video
-
Swedencare at Handelsbanken Nordic Mid Small Cap Seminar 2020
-
-
-
Q2
-
Reports
Presentations
Video
-
ABGSC Investor Day (Q2 2020)
-
Pareto Securities Annual Healthcare Conference 2020 (Q2 2020)
-
-
-
Q3
-
Reports
Presentations
Video
-
Presentation of Q3 2020
-
-
-
Q4
-
Reports
Video
-
Presentation of Q4 2020
-
-
-
Q1
- 2019
-
2018
-
Q1
-
Reports
Presentations
Video
-
Interview with CEO Håkan Lagerberg – Q1 2018
-
-
-
Q2
-
Reports
Presentations
Video
-
Sitdown interview with CEO Håkan Lagerberg – Q2 2018
-
Company presentation with CEO Håkan Lagerberg – Q2 2018
-
-
- Q3
-
Q4
-
Reports
Presentations
Video
-
Sitdown interview with CEO Håkan Lagerberg – Q4 2018
-
Company presentation with CEO Håkan Lagerberg – Q4 2018
-
-
-
Q1
- 2017
- 2016
-
2020
- Annual and Group Accounts
- Prospectus
For the current price and other share-related information,
please refer to Nasdaq First North Growth Market.
Nasdaq First North Growth Market is an alternative marketplace operated by OMX Nordic Exchange Stockholm. Companies whose shares are traded on Nasdaq First North Growth Market are not obliged to comply with the same rules as listed companies, but a less extensive regulatory framework applied to preferably smaller companies and growth companies. A placement in a company whose shares are traded on Nasdaq First North Growth Market may therefore be more risky than a placement in a listed company. All companies whose shares are traded on Nasdaq First North Growth Market have a Certified Adviser that oversees the company’s compliance with Nasdaq First North Growth Market’s regulatory framework for providing information to the market and investors. Certified Adviser reviews companies whose shares are to be traded on Nasdaq First North Growth Market. OMX Nordic Exchange Stockholm accepts the application for admission to such trade.
Click here for our current share price at Nasdaq First North Growth Market.
ISIN-code: SE0008294078
Shortname: SECARE
Certified Adviser:
FNCA Sweden AB – phone: +46(0)8 528 00 399 – Email: info@fnca.se – Address: Box 5807, 102 48 Stockholm, Sweden
Analysts and other monitoring
Swedencare Initiation report 20201203
Dividend
Swedencare will pay a dividend that takes into account the Group’s earnings development, consolidation and investment needs,
liquidity and financial position. The goal is to pay a dividend of 40 percent of the profit after tax.
Decision on dividend
The Annual General Meeting agreed on a dividend for the financial year 2019 of 0.70 SEK per share.
Ownership
Ownership structure per latest quarterly report
| Name | Shares | Shareholding (%) |
|---|---|---|
| HÅKAN SVANBERG & CO HEALTH CARE AB | 4,631,455 | 23.99% |
| DNCA INVESTMENTS | 1,526,136 | 7,91% |
| JCC GROUP INVEST SWEDEN AB (Johan Bergdahl through bolag) | 1,517,351 | 7.86% |
| MASTAN AB (Håkan Lagerberg through bolag) | 1,110,362 | 5.75% |
| AMF AKTIEFOND SMÅBOLAG | 926,000 | 4,80% |
| SEB NANOCAP | 734,172 | 3.80% |
| AKTIA ASSET MANAGMENT | 658,873 | 3.41% |
| SHB FONDER | 618,000 | 3.20% |
| JOH. BERENBERG, GOSSLER & CO. KG ACT OBO UNIVERSAL INV. FUNDS | 585,822 | 3.04% |
| ENTER SMÅBOLAGSFOND | 326,710 | 1,69% |
| INVESTMENT AB SPILTAN | 300,000 | 1.55% |
| MARTIN SHIMKO – MD Swedencare USA | 290,000 | 1.50% |
| CONSENSUS SMÅBOLAG | 272,000 | 1,41% |
| RBC INVESTOR SERVICES BANK S.A | 245,000 | 1,27% |
| NORDNET PENSIONSFÖRSÄKRING AB | 238,289 | 1.23% |
| ML, PIERCE FENNER & SMITH INC. | 222,173 | 1,15% |
| SWEDBANK ROBUR MICROCAP | 220,000 | 1,14% |
| IKC FONDER AB | 207,000 | 1,07% |
| LANNEBO NANOCAP | 205,000 | 1,06% |
| HANS PERSSON – MD Swedencare France | 199,750 | 1,03% |
| TEDCAP AB (Thomas Eklund through bolag) | 190,000 | 0,98% |
| FONDITA NORDIC MICRO CAP INVESTMENT | 184,769 | 0.96% |
| GRANDEUR, FUND BBHBOS | 170,982 | 0.89% |
| BFCM P/C BFCM SWEDEN RETAIL LT | 162,775 | 0,84% |
| CBNY-MKPGUE NAB ACF PIE GROWTH UK | 160,000 | 0,83% |
| AVANZA | 124,891 | 0.65% |
| PER MALMSTRÖM CONSULTING AB | 123,000 | 0,64% |
| CBNY-MKJGRO NAB ACF JUNO KIWISAVER | 100,000 | 0,52% |
| Others | 3,051,470 | 15.81% |
| Total | 19,301,980 | 100% |
| Free Float* | 11,694,812 | 60,59% |
Holdings include related parties.
* Shares not owned by board members, management, their affiliates, or shareholders with more than 10%.
Ownership structure per latest month
15 Largest shareholders
| Name | Shares | Shareholding (%) | Votes (%) |
|---|---|---|---|
| HÅKAN SVANBERG & CO HEALTH CARE AB | 4,631,455 | 21.97% | 21.97% |
| JCC GROUP INVEST SWEDEN AB (Johan Bergdahl) | 1,517,351 | 7.20% | 7.20% |
| DNCA FINANCE S.A | 1,355,428 | 6.43% | 6.43% |
| MASTAN AB (Håkan Lagerberg) | 1,110,362 | 5.27% | 5.27% |
| HANDELSBANKEN FONDER | 1,044,250 | 4.95% | 4.95% |
| AMF PENSION & FONDER | 959,500 | 4.55% | 4.55% |
| SEB FONDER | 848,072 | 4.02% | 4.02% |
| AKTIA ASSET MANAGEMENT | 669,196 | 3.17% | 3.17% |
| MATTHEW SHAW | 580,769 | 2.75% | 2.75% |
| CONSENSUS ASSET MANAGEMENT | 414,000 | 1.96% | 1.96% |
| BERENBERG FUNDS | 394,804 | 1.87% | 1.87% |
| NORDNET PENSIONSFÖRSÄKRING | 280,914 | 1.33% | 1.33% |
| MARTIN SHIMKO | 280,000 | 1.33% | 1.33% |
| ENTER FONDER | 279,710 | 1.33% | 1.33% |
| JASON BRAUN | 251,994 | 1.20% | 1.20% |
| Others | 6,466,670 | 30.67% | 30.67% |
| Sum 2021-01-31 | 21,084,475 | 100% | 100% |
Geographical distribution
| Country | Amount of known owners | Shares | Shareholding (%) | Votes (%) |
|---|---|---|---|---|
| SWEDEN | 9,754 | 14,261,149 | 67.63% | 67.64% |
| FRANCE | 6 | 1,653,118 | 7.84% | 7.84% |
| FINLAND | 100 | 1,145,426 | 5.43% | 5.43% |
| UNITED STATES | 14 | 961,920 | 4.57% | 4.57% |
| GERMANY | 9 | 741,450 | 3.52% | 3.52% |
| UNITED KINGDOM | 15 | 667,487 | 3.17% | 3.17% |
| LUXEMBURG | 10 | 356,623 | 1.69% | 1.69% |
| NORWAY | 21 | 274,376 | 1.30% | 1.30% |
| NEW ZEALAND | 1 | 180,000 | 0.85% | 0.85% |
| SWITZERLAND | 12 | 131,694 | 0.62% | 0.62% |
| Other countries | 85 | 17,835 | 0.09% | 0.09% |
| Anonymous ownership | 693,397 | 3.28% | 3.28% | |
| Sum 2021-01-31 | 10,027 | 21,084,475 | 100% | 100% |
Holdings
| Ownership distribution by holding | Amount of owners | Capital (%) | Votes (%) | Number of known owners |
|---|---|---|---|---|
| 1 – 100 | 201,613 | 0.96% | 0.96% | 8,087 |
| 101 – 250 | 150,797 | 0.72% | 0.72% | 926 |
| 251 – 1000 | 366,488 | 1.74% | 1.74% | 724 |
| 1001 – 5000 | 403,222 | 1.91% | 1.91% | 200 |
| 5001 – 25000 | 420,078 | 1.99% | 1.99% | 36 |
| 25001 – 100000 | 1,049,879 | 4.98% | 4.98% | 20 |
| 100001 – 500000 | 5,082,618 | 24.11% | 24.11% | 25 |
| 500001 – 1000000 | 3,057,537 | 14.50% | 14.50% | 4 |
| 1000001 – | 9,658,846 | 45.81% | 45.81% | 5 |
| Anonymous ownership | 693,397 | 3.28% | 3.28% | |
| Sum 2021-01-31 | 21,084,475 | 100% | 100% | 10,027 |
Concentration
*Per 2021-01-31
| Type of Concentration | Concentration | Shareholding (%) | Votes (%) | Shares |
|---|---|---|---|---|
| The 10 largest owners | 10 | 62.28% | 62.28% | 13,130,383 |
| The 20 largest owners | 20 | 74.29% | 74.29% | 15,664,320 |
| The 30 largest owners | 30 | 82.20% | 82.21% | 17,332,408 |
Links to public presentations
of Swedencare AB (publ).
| Date | Description | Download | Video |
|---|---|---|---|
| 7 September, 2020 | Swedencare AB (publ) – Swedencare at ABGSC Investor Day 2020 |  |
|
| 2 September, 2020 | Swedencare AB (publ) – Swedencare at Pareto Securities Annual Healthcare Conference 2020 | |
|
| 10 June, 2020 | Swedencare AB (publ) – Swedencare at Handelsbanken Nordic Mid Small Cap Seminar 2020 | |
|
| 3 September, 2019 | Swedencare AB (publ) – Swedencare at Introduce Investor Days 2019 (Q2 2019) | |
|
| 3 September, 2019 | Swedencare AB (publ) – Interview with CEO Håkan Lagerberg at Introduce Investor Days 2019 (Q2 2019) | |
|
| 15 March, 2019 | Swedencare AB (publ) – Sit-down interview with CEO Håkan Lagerberg (Q4 2018) | |
|
| 15 March, 2019 | Swedencare AB (publ) – Company presentation with CEO Håkan Lagerberg (Q4 2018) | |
|
| 4 September, 2018 | Swedencare AB (publ) – Sit-down interview with CEO Håkan Lagerberg (Q2 2018) | |
|
| 4 September, 2018 | Swedencare AB (publ) – Company presentation with CEO Håkan Lagerberg (Q2 2018) | |
|
| 26 April, 2018 | Swedencare AB (publ) – Interview with CEO Håkan Lagerberg (Q1 2018) | |
|
| 20 April, 2018 | Swedencare AB (publ) – Remiums analys till institutioner, köp riktkurs 44 SEK |  |
|
| 11 September, 2017 | Swedencare AB (publ) – Investor Presentation SvD Börsplus 11 Sept 2017 | |
|
| 30 August, 2016 | Swedencare AB (publ) – Interim Report (Q2 2016) | |
|
| 21 April, 2016 | Swedencare AB (publ) – Company Presentation | |
Content
Extra bolagsstämma 2020
-2020-banner-large.jpg)
Fullmaktsformulär extra årsstämma Swedencare AB (publ)
Kallelse extra bolagsstämma Swedencare AB (publ) 20200911
Styrelsens förslag till beslut om bemyndigande – Extra bolagsstämma 20200911
Instruktioner för poströstning (Extra bolagsstämma den 11 september 2020)
Formulär poströstning (Extra bolagsstämma den 11 september 2020)
Årsstämma 2020
-2020-banner.jpg)
VD’s anförande
Styrelsens förslag – bemyndigande för styrelsen – emission av aktier
Styrelsens förslag till incitamentsprogram
Fullmaktsformulär årsstämma Swedencare AB (publ)
Kallelse årsstämma Swedencare AB (publ) 2020
Swedencare AB (publ) – Årsredovisning 2019
Legal Organization /
Board and Management.
 - Legal Organization-en.jpg)
Swedencare
The parent company Swedencare AB (publ) is responsible for the strategy, business planning and management. This is done by the control of trademarks and patents, sales rights, cooperation agreements and as parent company of the subsidiaries. The Company and headquarter is located at Medeon Science Park in Malmö, Sweden.
Subsidiaries/Sales Company
Swedencare owns 100% of the shares to all subsidiaries/sales companies which are responsible for the sales and marketing for its individual regions. The subsidiaries provide a monthly financial report as well as a sales progress to Swedencare. The group also have a common ERP-system where orders and invoices are registered. The system enable an effective production planning at the same time as the subsidiaries can track the order progress. Through the local market knowledge of the subsidiaries the marketing can be customized and the local customer preferences and new products can easily and effectively be identified. The subsidiaries are located and managed in Greece, Spain, France, Great Britain, Ireland, Sweden and the US.
Board of Directors (BoD) and Management
The Board of Directors are responsible for the Company’s strategic and financial targets and, together with the management, for the strategic planning. In the BoD, there is an extensive experience of international sales and marketing as well as a wide international network. The Managing Director and CFO are responsible to provide a business plan in line with the BoDs strategic and financial targets. They are also responsible for financial planning, and questions and communication with the stock exchange. The CEO of the Company, together with the managing directors of the subsidiaries, is a management team responsible for product development as well as sales and marketing.
Board of Directors of Swedencare
-Board-Members.jpg)
-Board-Member-Per-Malmstrom.jpg) |
Per MalmströmPresident of the Board since 2014 – Born 1961.• Background from the financial sector, among others SEB, Aragon Fondkommission, CFO at Adera AB 1998-2001 (Addnode AB), as well as several Board assignments. Bachelor of economics from Örebro Högskola. • Managing Director and member of the board at Per Malmström Consulting AB. President of the board in K3 Nordic AB, K3 Travel AB, SVANBERG & CO INVEST AB, Creative Tools, Northway Partners, Deligate AB.
Independent in relation to the company/company management: Yes |
-Board-Member-Hakan-Lagerberg.jpg) |
Håkan LagerbergMember of the board since 2014 – Born 1968.• International experience from leading positions in private and public companies. International Jur. Kand from Lunds University. Post graduate in International Trade Law from University of Torino in Italy. • Chairman of the Board of One CC AB. Member of the Board of Directors of Polygiene AB (publ), HAOLAG AB and Mastan AB.
Independent in relation to the company/company management: No |
-Board-Member-Johan-Bergdahl.jpg) |
Johan BergdahlMember of the board since 2014 – Born 1970.• Entrepreneur and owner to several companies within sales, IT and property management. Degree in Market economy from Nercia Business School. • President of the board in Local Market Sweden AB and BR Group AB. Member of the board in Comera AB, JCC Group AB, JCC Group Invest AB, Junikvisten 10 AB, Rostastrand Holding AB, BR Group Holding AB, BR Group Fastigheter AB, Storgatan Fastigheter AB and Trygghandel AB.
Independent in relation to the company/company management: Yes |
-Board-Member-Tomas-Eklund_.jpg) |
Thomas EklundMember of the board since 2016 – Born 1967.
• Advisor to Patricia AB (Investor AB) and former Managing Director of Investor Growth Capital in Europe. • Board member of Boule Diagnostics AB, Biotage AB, Rodebjer Form AB and Immedica Pharma AB.
Independent in relation to the company/company management: Yes |
-Board-Member-Hakan-Svanberg.jpg) |
Håkan SvanbergMember of the board since 2014 – Born 1957.• Entrepreneur and owner to several companies within IT, travel and finance. Master in Philosophy from Örebro University. • Managing Director in SVANBERG & CO INVEST AB. Member of the board in Creative Tools, Deligate AB, EyeonID Group AB, K3 Nordic AB, SVANBERG & CO INVEST AB, H. Svanberg Software Holding, Northway Partners, Svanberg Factoring, Treberg Holding AB, Kontosmart AB. Deputy of the board in Chief Holding AB and SWG Holding AB.
Independent in relation to the company/company management: Yes |
-Board-Member-Sara-Brandt.jpg) |
Sara BrandtMember of the board since 2019 – Born 1963.
• Vice President Almi Företagspartner, former VP and CEO Berner Nordic and before that senior positions on ia. Cederroth Nordic, Coca-Cola Sweden, Unilever Nordic and UK. Long background from international B2C and B2B companies and broad experience from several industries and product categories such as consumer health and international distributor activities.
Independent in relation to the company/company management: Yes |
* Own or related holdings of shares and other financial instruments in Swedencare. Holding by December 31, 2020.
Management
 |
Håkan LagerbergCEO• See info above.
|
 |
Jenny GraflindCFO• Jenny has been employed since 2017.
• A long international background as CFO and previously as, among other functions Financial Controller
Board member of USWE. |
Responsible at Swedencare’s subsidiaries
 |
Jason BraunMD of the subsidiary Animal Pharm Care USA Inc• Jason has been employed since 2003.
• Over 25 years of experience from the animal health industry. Founder and MD of Animal Pharmaceuticals since 2003.
No other assignments. |
 |
Ed HoldenMD of the subsidiary Holden2 LLC• Ed has been employed since 2011.
• Over 10 years of experience in Internet Marketing and eCommerce. Founder and MD of Holden2 since 2011.
No other assignments. |
 |
John LeonardMD of the subsidiaries Swedencare UK Ltd and Swedencare Ireland• John has been employed since 2004.
• Over 20 years of experience from the Oralhealth industry as Sales Manager at TePe and Colgate and development manager at CTS dental.
No other assignments. |
 |
Brian NugentMD of the subsidiary StratfordCare USA Inc• Brian has been employed since 2011.
• Over 20 years experience as founder, COO and CEO of multiple successful animal health companies based in the United States.
No other assignments. |
 |
Hans PerssonMD of the subsidiary SARL Buccosanté• Hans is employed since 2008.
• Experience of international marketing, distribution and sales as well as 25 years of experience in leading smaller companies in the French market.
No other assignments. |
__.png) |
Ioanna PsychogiouCountry Manager of the subsidiary Biovet• Ioanna has been employed since 2012.
• Background as manager of Biovet and experience in the pet and veterinary markets.
No other assignments. |
 |
Matthew ShawMD of the subsidiary Nutravet UK Ltd• Matthew has been employed since 2008.
• Entrepreneurial background across various sectors. Expertise in building brands with a keen eye for detail
No other assignments. |
 |
Martin ShimkoMD of the subsidiary SwedencareUSA Inc• Martin has been employed since 2005.
• A background as management trainee from NASSCO and the management group in The Bohle Co.
No other assignments. |
 |
Raquel ToscaCountry Manager of the subsidiary Swedencare Spain SLU• Raquel has been employed since 2019. • An international background of international business, marketing and communication at the latest from the animal health company Laboratorios Calier. Master’s degree in Marketing, Communication & Digital Publicity from UOC University in Barcelona and Inesdi Digital Business School.
No other assignments. |
 |
Sabine UhdeHead of the Nordic subsidiary Swedencare Nordic AB• Sabine has been employed since 2015.
• Background as department manager and from the marketing department on TT-line.
No other assignments. |
Articles of Association for
Swedencare AB (publ) (556470-3790)
§ 1 COMPANY NAME
The company name is Swedencare AB (publ). Public company.
§ 2 REGISTERED OFFICE
The registered head office of the company is in the municipality of Malmö.
§ 3 OBJECTS OF THE COMPANY
The company objective is, directly or indirectly, the development, manufacture and sale of products within the area of animal healthcare and preventive dental care and other business compatible therewith.
§ 4 SHARE CAPITAL
The share capital shall be not less than SEK 500,000 and not more than SEK 2,000,000.
§ 5 NUMBER OF SHARES
The number of shares shall be not less than 10,000,000 and not more than 40,000,000.
§ 6 FINANCIAL YEAR
The company’s financial year shall be calendar year.
§ 7 BOARD OF DIRECTORS
The board of directors shall consist of not less than three and not more than seven board members with not more than two deputy board members. The board members and deputy board members are elected annually for the period until the close of the first annual general meeting held after the year in which the board member or deputy board member was appointed.
§ 8 AUDITOR
For audit of the company’s annual report, the accounts and the administration of the board of directors and managing director, not less than one auditor and not more than two auditors with or without deputy auditors shall be elected.
§ 9 ANNUAL GENERAL MEETING
The following matters shall be addressed at the Annual General Meeting:
1. Election of a chairman at the meeting;
2. Preparation and approval of the voting list;
3. Election of one (1) or two (2) persons to verify the minutes of the meeting;
4. Approval of the agenda;
5. Determination of whether the meeting was duly convened;
6. Submission of the annual report and the auditor’s report, and if applicable, the group accounts and the auditor’s report for the group;
7. Resolutions:
(a) regarding the adoption of the income statement and balance sheet, and if applicable, the consolidated income statement and the consolidated balance sheet
(b) regarding allocation of profit or loss in accordance with the adopted balance sheet
(c) regarding the discharge from liability of the board members and, where applicable, of the managing director;
8. Determination of fees for the board of directors and, where applicable, for the auditors;
9. Election of the board of directors and auditors; and
10. Other matters which rest upon the meeting according to the Swedish Companies Act or the company’s articles of association.
§ 10 NOTICE TO ATTEND
Notice to attend a general meeting shall be advertised in Post- och Inrikes Tidningar (The Official Swedish Gazette) and on the company website. At the time of notice, information about the notice shall be advertised in Dagens Industri. The notice shall immediately, and at no cost for the recipient, be sent by post to those shareholders who so request and state their address.
Notice to attend an annual general meeting and notice to attend an extraordinary general meeting at which the issue of alterations of the articles of association is to be addressed shall be issued not earlier than six weeks and not later than four weeks prior to the meeting. Notice to attend an extraordinary general meeting other than such as mentioned above shall be issued not earlier than six weeks and not later than two weeks prior to the general meeting.
§ 11 APPLICATION IN ADVANCE
A shareholder, who wishes to participate at the general meeting, shall (i) be included in the transcript or other record of the share register as of five days before the meeting (ii) notify the company thereof not later than on the date specified in the notice to attend the general meeting. Such a date may not be a Sunday, other public holiday, Saturday, Midsummer Eve, Christmas Eve or New Year’s Eve and may not occur earlier than the fifth weekday prior to the general meeting. If the notice to attend the general meeting does not state a last day for notification, then notification is not required in order to participate at the general meeting. A shareholder who wishes to be accompanied by advisors at a general meeting shall state the number of advisors (not more than two) accompanying the shareholder in the application.
§ 12 CSD CLAUSE
The company’s shares shall be registered in a CSD (central securities depository) register in accordance with the Financial Instruments (Accounts) Act (1998:1479).
Articles of Association adopted at the general meeting held on March 7, 2016.
Audit
At the 2019 Annual General Meeting, the authorized auditing firm Grant Thornton Sweden AB was reappointed for an additional one-year period up to and including the 2020 Annual General Meeting.
The auditor reviews the company’s annual report, interim report for the second quarter and accounting, as well as the Board’s and the CEO’s administration.
Swedencare’s AUDITOR
Ann Theander
Principal auditor
Authorized Public Accountant at Grant Thornton Sweden AB.
Auditor in the group since 2018.
Swedencare AB (publ)
Follow Swedencare’s news feed
Sign up for our news
and press releases
Stay up-to-date with the latest news about us, delivered right to your inbox!